SMA Research Platform

Evidence graph for Spinal Muscular Atrophy

Biology-first target discovery
Christian Fischer / Bryzant Labs
14,766Targets
453Trials
84Drugs
7Datasets
6,987Sources
64,683Claims
72,052Evidence
29,649Hypotheses
DRUGapprovedsmall molecule

givinostat

Mechanism

HDAC class I + IIb inhibitor. FDA approved 2024-03-21 for Duchenne Muscular Dystrophy (Duvyzat, Italfarmaco). SMA repurposing candidate per Osseni 2026.

Structure

ON=C(/C=C/c1ccc(CN2CCN(Cc3ccc(C(=O)N(C)CC4CCCO4)cc3)CC2)cc1)O

Related claims (0)

No claims matched “givinostat” in free-text search.

Off-Target Findings (0)

No Boltz-2 / Chai-1 off-target panel claims recorded for this drug.

Login → Command Center